Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Ravi Vij; Jonathan L. Kaufman; Andrzej J Jakubowiak; Michael Wang; Sundar Jagannath; Vishal Kukreti; Kevin T. McDonagh; Melissa Alsina; Nizar J Bahlis; Andrew R Belch; Frederic J. Reu; Nashat Y. Gabrail; Jeffrey Matous; David H. Vesole; Robert Z. Orlowski; Sandra Wear; Lori Kunkel; Alvin F. Wong; Peter Lee; Keith Stewart

doi:10.1182/BLOOD.V118.21.813.813

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Ravi Vij
, Jonathan L. Kaufman
, Andrzej J Jakubowiak
, Michael Wang
, Sundar Jagannath
, Vishal Kukreti
, Kevin T. McDonagh
, Melissa Alsina
, Nizar J Bahlis
, Andrew R Belch
, Frederic J. Reu
, Nashat Y. Gabrail
, Jeffrey Matous
, David H. Vesole
, Robert Z. Orlowski
, Sandra Wear
, Lori Kunkel
, Alvin F. Wong
, Peter Lee
, Keith Stewart

Washington University in St. Louis
Emory University
University of Chicago
University of Texas MD Anderson Cancer Center
Mount Sinai Hospital
Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada,
University of Kentucky
Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA,
University of Calgary
Cross Cancer Institute
Taussig Cancer Center, Cleveland, OH, USA,
Gabrail Cancer Center, Canton, OH, USA,
Rocky Mountain Cancer Center, Denver, CO, USA,
Hackensack University Medical Center
Multiple Myeloma Research Consortium, Norwalk, CT, USA,
NA, San Francisco, CA,
Onyx Pharmaceuticals
Roy and Patricia Disney Family Cancer Center, Burbank, CA, USA,
Mayo Clinic

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	118
Issue number	21
DOIs	https://doi.org/10.1182/BLOOD.V118.21.813.813
State	Published - Nov 18 2011
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD.V118.21.813.813License: Unspecified

Cite this

Vij, R., Kaufman, J. L., Jakubowiak, A. J., Wang, M., Jagannath, S., Kukreti, V., McDonagh, K. T., Alsina, M., Bahlis, N. J., Belch, A. R., Reu, F. J., Gabrail, N. Y., Matous, J., Vesole, D. H., Orlowski, R. Z., Wear, S., Kunkel, L., Wong, A. F., Lee, P., & Stewart, K. (2011). Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood, 118(21). https://doi.org/10.1182/BLOOD.V118.21.813.813

Vij, R, Kaufman, JL, Jakubowiak, AJ, Wang, M, Jagannath, S, Kukreti, V, McDonagh, KT, Alsina, M, Bahlis, NJ, Belch, AR, Reu, FJ, Gabrail, NY, Matous, J, Vesole, DH, Orlowski, RZ, Wear, S, Kunkel, L, Wong, AF, Lee, P & Stewart, K 2011, 'Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM', Blood, vol. 118, no. 21. https://doi.org/10.1182/BLOOD.V118.21.813.813

@article{1b55e47f33cf4936b76923b20a5be158,

title = "Final Results From the Bortezomib-na{\"i}ve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM",

author = "Ravi Vij and Kaufman, \{Jonathan L.\} and Jakubowiak, \{Andrzej J\} and Michael Wang and Sundar Jagannath and Vishal Kukreti and McDonagh, \{Kevin T.\} and Melissa Alsina and Bahlis, \{Nizar J\} and Belch, \{Andrew R\} and Reu, \{Frederic J.\} and Gabrail, \{Nashat Y.\} and Jeffrey Matous and Vesole, \{David H.\} and Orlowski, \{Robert Z.\} and Sandra Wear and Lori Kunkel and Wong, \{Alvin F.\} and Peter Lee and Keith Stewart",

note = "653. Myeloma - Therapy, excluding Transplantation: Novel drugs in relapsed/refractory myeloma patients | Ravi Vij, Jonathan L. Kaufman, Andrzej J Jakubowiak, Michael Wang, Sundar Jagannath, Vishal Kukreti, Kevin T. McDonagh, Melissa Alsina, Nizar J Bahlis, Andrew R Belch, Frederic J. Reu, Nashat Y. Gabrail, Jeffrey Matous, David H. Vesole, Robert Z.",

year = "2011",

month = nov,

day = "18",

doi = "10.1182/BLOOD.V118.21.813.813",

language = "American English",

volume = "118",

journal = "Blood",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

AU - Vij, Ravi

AU - Kaufman, Jonathan L.

AU - Jakubowiak, Andrzej J

AU - Wang, Michael

AU - Jagannath, Sundar

AU - Kukreti, Vishal

AU - McDonagh, Kevin T.

AU - Alsina, Melissa

AU - Bahlis, Nizar J

AU - Belch, Andrew R

AU - Reu, Frederic J.

AU - Gabrail, Nashat Y.

AU - Matous, Jeffrey

AU - Vesole, David H.

AU - Orlowski, Robert Z.

AU - Wear, Sandra

AU - Kunkel, Lori

AU - Wong, Alvin F.

AU - Lee, Peter

AU - Stewart, Keith

N1 - 653. Myeloma - Therapy, excluding Transplantation: Novel drugs in relapsed/refractory myeloma patients | Ravi Vij, Jonathan L. Kaufman, Andrzej J Jakubowiak, Michael Wang, Sundar Jagannath, Vishal Kukreti, Kevin T. McDonagh, Melissa Alsina, Nizar J Bahlis, Andrew R Belch, Frederic J. Reu, Nashat Y. Gabrail, Jeffrey Matous, David H. Vesole, Robert Z.

PY - 2011/11/18

Y1 - 2011/11/18

UR - https://ashpublications.org/blood/article/118/21/813/83029/Final-Results-From-the-Bortezomib-nai-ve-Group-of

U2 - 10.1182/BLOOD.V118.21.813.813

DO - 10.1182/BLOOD.V118.21.813.813

M3 - Article

VL - 118

JO - Blood

JF - Blood

IS - 21

ER -

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Disciplines

Access to Document

Other files and links

Cite this